A metal-drug self-delivery nanomedicine alleviates tumor immunosuppression to potentiate synergistic chemo/chemodynamic therapy against hepatocellular carcinoma.

ABSTRACT: Hepatocellular carcinoma (HCC) is the most common primary liver cancer with a poor prognosis. Chemotherapy is one of the first-line clinical therapeutic strategies for HCC. Still, the effectiveness of chemotherapy is hampered by the tumor immunosuppressive microenvironment and drug resistance caused by insufficient delivery. Herein, we developed a metal-drug self-delivery nanomedicine (FDAH) to improve the chemo/chemodynamic therapeutic efficacy of HCC. The core of FDAH is an iron-based nanoparticle chelated with two clinical drugs, Doxorubicin (DOX) and Plerixafor (AMD3100). Additionally, the nanomedicine is externally modified with a hyaluronic acid (HA) shell, which can prolong the circulation time of the nanoparticles in the bloodstream after intravenous administration. After entering

SUBMITTER: Guo C 

PROVIDER: S-EPMC12327863 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature